PicoCELA Inc. (NASDAQ:PCLA) Short Interest Up 77.2% in July

PicoCELA Inc. (NASDAQ:PCLA) saw a significant growth in short interest in July. As of July 15th, there was short interest totaling 201,780 shares, a growth of 77.2% from the June 30th total of 113,864 shares. Currently, 504.5% of the company’s stock are sold short. Based on an average daily trading volume, of 503,315 shares, the short-interest ratio is presently 0.4 days.

Hedge Funds Weigh In On PicoCELA

An institutional investor recently bought a new position in PicoCELA stock. Jane Street Group LLC acquired a new stake in PicoCELA Inc. (NASDAQ:PCLA) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 172,132 shares of the company’s stock, valued at approximately $52,000. Jane Street Group LLC owned about 18.92% of PicoCELA as of its most recent SEC filing.

PicoCELA Stock Down 0.8%

PCLA stock traded down $0.04 on Friday, hitting $5.14. 48,631 shares of the company’s stock were exchanged, compared to its average volume of 739,752. The firm has a 50 day moving average price of $5.80 and a two-hundred day moving average price of $4.31. PicoCELA has a 12-month low of $1.35 and a 12-month high of $16.80.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on PCLA. Weiss Ratings raised PicoCELA from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 20th. Wall Street Zen upgraded PicoCELA to a “hold” rating in a research note on Saturday, July 25th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has a consensus rating of “Sell”.

About PicoCELA

PicoCELA, Inc is a clinical-stage biotechnology company focused on the development of next-generation vaccines and immunotherapies based on its proprietary self-assembling protein nanoparticle platform. The company engineers functionalized, virus-like protein particles designed to present disease-relevant antigens in their native conformation, with the goal of eliciting potent B-cell and T-cell responses. PicoCELA’s platform enables the rapid design and production of vaccine candidates against infectious diseases as well as antigen-specific immunotherapies for certain cancers.

The company’s pipeline includes vaccine programs targeting SARS-CoV-2 and other respiratory pathogens, leveraging its nanoparticle scaffolds to display full-length viral spike proteins or other key antigens.